Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06668805 · ClinicalTrials.gov registry record · Phase 2
A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
A Phase 2 study of Turner Syndrome and Noonan Syndrome, sponsored by BioMarin Pharmaceutical.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 20
- Study locations
NCT06668805 is a Phase 2 study of Turner Syndrome and Noonan Syndrome that is actively recruiting participants, run by BioMarin Pharmaceutical. The registered enrollment target is 54 participants, below the 515-participant average among 14 other Turner Syndrome trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 18 states.
The verdict
NCT06668805, a Phase 2 study of Turner Syndrome and Noonan Syndrome, is actively recruiting participants, sponsored by BioMarin Pharmaceutical.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this basket study in children with Turner syndrome, SHOX deficiency, and Noonan syndrome is to evaluate the effect of 3 doses of vosoritide on growth as measured by AGV after 6 months of treatment. The long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up to FAH.
Conditions Studied
Interventions
- DRUG Vosoritide Injection
Study Locations (20)
New York
- Icahn School of Medicine at Mount Sinai - New York
- Children's Hospital at Montefiore - The Bronx
Texas
- Children's Medical Center Dallas - Dallas
- University of Texas Health Science Center at Houston (UT Health) - Houston
California
- Children's Hospital of Orange County Main Campus - Orange - Orange
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- Nemours Children's Hospital, Delaware (Alfred I. Dupont Hospital for Children) - Wilmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Nicklaus Children's Hospital - Miami
Idaho
- St. Luke's Children's Endocrinology and Diabetes - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2041-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06668805
The ClinicalTrials.gov registry entry for NCT06668805 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 515-participant average among 14 other Turner Syndrome trials with a reported enrollment target (90% lower). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Turner Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Vosoritide Injection is the first listed.
NCT06668805 reports 20 study locations spanning 18 distinct geographic areas - top geographies include New York, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06668805 about?
NCT06668805 is a clinical study titled "A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment". The purpose of this basket study in children with Turner syndrome, SHOX deficiency, and Noonan syndrome is to evaluate the effect of 3 doses of vosoritide on growth as measured by AGV after 6 months of treatment. The long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluat...
What is the current status of trial NCT06668805?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2024-11-22. Estimated completion is 2041-09.
What conditions does trial NCT06668805 study?
This clinical trial studies the following conditions: Turner Syndrome, Noonan Syndrome, Short Stature Homeobox- Containing Gene SHOX Deficiency.
What interventions are being tested in trial NCT06668805?
The interventions under investigation include: Vosoritide Injection (DRUG).
Who is sponsoring clinical trial NCT06668805?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06668805 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Turner Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vosoritide for Short Stature in Turner Syndrome
RECRUITING · Phase 2
-
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Natural History of Noncirrhotic Portal Hypertension
RECRUITING
-
UTHealth Turner Syndrome Research Registry
RECRUITING
-
Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
RECRUITING · Phase 4
-
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.